Skip to main content
. 2022 Aug 4;22:289. doi: 10.1186/s12883-022-02805-z

Table 1.

Baseline data

Experimental group (n = 60) Control group (n = 59)
Demographic characteristics
 Male (%) 34 (57) 36 (61)
 Age (y) ± SD, range 64.7 ± 8.9, 44–86 63.9 ± 10.6, 44–85
Stroke type
 TIA (%) 34 (57) 27 (56)
 Ischemic stroke (%) 26 (43) 32 (54)
Stroke localization
 Left (%) 30 (50) 31 (53)
 Right (%) 18 (30) 16 (27)
 Vertebrobasilar (%) 12 (20) 11 (19)
Vascular risk factors
 Waist circumference in cm ± SD 96.7 ± 11.2 96.4 ± 10.9
 Systolic blood pressure (mmHg) ± SD 124.5 ± 15.0 123.2 ± 15.2
 Diastolic blood pressure (mmHg) ± SD 74.9 ± 9.6 74.3 ± 9.6
 Hypertensiona (%) 48 (80) 44 (73)
 Anti-hypertensive treatment (%) 41 (68) 42 (71)
 LDL-cholesterol (mmol/l) ± SD 2.3 ± 0.7 2.3 ± 0.7
 Hypercholesterolemia (%) 47 (78) 37 (62)
 NIHSS, median (IQR) 0 (1) 0 (1)
 Active smoking (%) 7 (12) 14 (24)
 History of smoking (%) 26 (43) 34 (58)
 Alcohol overuse (%) 4 (7) 6 (10)
 History of stroke (%) 15 (25) 13 (27)
 Atrial fibrillation (%) 0 (0) 2 (3)
 History of myocardial infarction or other cardiac ischemia (%) 9 (15) 11 (19)
 History of other cardiac illness (%) 49 (82) 50 (85)
 History of other cardiovascular disease (%) 42 (70) 40 (68)
 Peripheral Artery Disease (%) 1 (2) 2 (3)
 Family history of stroke (%) 25 (42) 25 (42)
 Diabetes (%) 5 (8) 9 (15)
Other outcomes
 MoCA (0–30) ± SD 24.9 ± 3.2 25.5 ± 2.9
 VO2max (ml/kg/min) ± SD 23 ± 6.5 22 ± 6.4
 PASE (0–361) ± SD 133.8 ± 64.7 117.5 ± 68.9
 HADS (0–42) ± SD 8.3 ± 5.7 10.3 ± 6.6
 FSS 1-7 ± SD 3.7 ± 1.5 4.0 ± 1.6
 History of COPD or asthma (%) 3 (5) 3 (5)
 OSAS (%) 2 (3) 3 (5)
 Thrombolysisb (%) 4 (7) 6 (10)
 Time from TIA/stroke to randomization, in days (median) 30 21

Values are given as means with standard deviation (SD) with range or as number (percentage), unless otherwise stated.

aBased on medical history, use of antihypertensive treatment, or blood pressure > 140/90 mmHg

bHaving received thrombolysis treatment for the ischemic event at presentation